메뉴 건너뛰기




Volumn 3, Issue 3, 2008, Pages 212-216

Novel therapeutic options in metastatic renal cancer - Review and Post ASCO 2007 update

Author keywords

Antiangiogenic agents; ASCO 2007; Combination regime; Renal cell carcinoma; Targeted therapies; Tyrosine kinase inhibitor

Indexed keywords

AXITINIB; BEVACIZUMAB; CEDIRANIB; ERLOTINIB; EVEROLIMUS; INTERFERON; INTERLEUKIN 2; PAZOPANIB; PERIFOSINE; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VATALANIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; INDOLE DERIVATIVE; MAMMALIAN TARGET OF RAPAMYCIN; MONOCLONAL ANTIBODY; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE; RAPAMYCIN; VASCULOTROPIN A;

EID: 54049131744     PISSN: 15748871     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488708785700311     Document Type: Review
Times cited : (9)

References (37)
  • 1
    • 20344362911 scopus 로고    scopus 로고
    • Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours
    • Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005; 92: 1855-61.
    • (2005) Br J Cancer , vol.92 , pp. 1855-1861
    • Awada, A.1    Hendlisz, A.2    Gil, T.3
  • 2
    • 27144527372 scopus 로고    scopus 로고
    • Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors
    • Moore M, Hirte HW, Siu L, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005; 16: 1688-94.
    • (2005) Ann Oncol , vol.16 , pp. 1688-1694
    • Moore, M.1    Hirte, H.W.2    Siu, L.3
  • 3
    • 33744984843 scopus 로고    scopus 로고
    • Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma
    • Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505-12.
    • (2006) J Clin Oncol , vol.24 , pp. 2505-2512
    • Ratain, M.J.1    Eisen, T.2    Stadler, W.M.3
  • 4
    • 35548931472 scopus 로고    scopus 로고
    • Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results
    • Szczylik C, Demkow T, Staehler M, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results. J Clin Oncol (Meeting Abstracts) 2007; 25: 5025.
    • (2007) J Clin Oncol (Meeting Abstracts) , vol.25 , pp. 5025
    • Szczylik, C.1    Demkow, T.2    Staehler, M.3
  • 5
    • 37549061995 scopus 로고    scopus 로고
    • A phase II trial of intrapatient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC)
    • Amato RJ, Harris P, Dalton M, et al. A phase II trial of intrapatient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). J Clin Oncol (Meeting Abstracts) 2007; 25: 5026.
    • (2007) J Clin Oncol (Meeting Abstracts) , vol.25 , pp. 5026
    • Amato, R.J.1    Harris, P.2    Dalton, M.3
  • 6
    • 33846148701 scopus 로고    scopus 로고
    • Sorafenib in Advanced Clear-Call Renal-Cell Carcinoma
    • Escudier B, Eisen T, Stadler WM, et al. Sorafenib in Advanced Clear-Call Renal-Cell Carcinoma. N Engl J Med 2007; 356: 125-34.
    • (2007) N Engl J Med , vol.356 , pp. 125-134
    • Escudier, B.1    Eisen, T.2    Stadler, W.M.3
  • 8
    • 33644833910 scopus 로고    scopus 로고
    • Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
    • Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16-24.
    • (2006) J Clin Oncol , vol.24 , pp. 16-24
    • Motzer, R.J.1    Michaelson, M.D.2    Redman, B.G.3
  • 9
    • 33744954585 scopus 로고    scopus 로고
    • Sunitinib in patients with metastatic renal cell carcinoma
    • Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 2516-24.
    • (2006) JAMA , vol.295 , pp. 2516-2524
    • Motzer, R.J.1    Rini, B.I.2    Bukowski, R.M.3
  • 10
    • 33750631676 scopus 로고    scopus 로고
    • Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC)
    • Rini BI, George DJ, Michaelson MD, et al. Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC). J Clin Oncol (Meeting Abstracts) 2006; 24: 4522.
    • (2006) J Clin Oncol (Meeting Abstracts) , vol.24 , pp. 4522
    • Rini, B.I.1    George, D.J.2    Michaelson, M.D.3
  • 11
    • 33846181370 scopus 로고    scopus 로고
    • Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
    • Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24.
    • (2007) N Engl J Med , vol.356 , pp. 115-124
    • Motzer, R.J.1    Hutson, T.E.2    Tomczak, P.3
  • 12
    • 35548945277 scopus 로고    scopus 로고
    • Continuous daily administration of sunitinib in patients (pts) with cytokine-refractory metastatic renal cell carcinoma (mRCC: Updated results
    • Srinivas S, Roigas J, Gillessen S, et al. Continuous daily administration of sunitinib in patients (pts) with cytokine-refractory metastatic renal cell carcinoma (mRCC: Updated results. J Clin Oncol (Meeting Abstracts) 2007; 25: 5040.
    • (2007) J Clin Oncol (Meeting Abstracts) , vol.25 , pp. 5040
    • Srinivas, S.1    Roigas, J.2    Gillessen, S.3
  • 14
    • 34249779568 scopus 로고    scopus 로고
    • Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
    • Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-81.
    • (2007) N Engl J Med , vol.356 , pp. 2271-2281
    • Hudes, G.1    Carducci, M.2    Tomczak, P.3
  • 15
    • 33746651683 scopus 로고    scopus 로고
    • A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC)
    • Amato RJ, Misellati A, Khan M, Chiang S. A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). J Clin Oncol (Meeting Abstracts) 2006; 24: 4530.
    • (2006) J Clin Oncol (Meeting Abstracts) , vol.24 , pp. 4530
    • Amato, R.J.1    Misellati, A.2    Khan, M.3    Chiang, S.4
  • 17
    • 0042343801 scopus 로고    scopus 로고
    • A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
    • Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-34.
    • (2003) N Engl J Med , vol.349 , pp. 427-434
    • Yang, J.C.1    Haworth, L.2    Sherry, R.M.3
  • 18
    • 35549006672 scopus 로고    scopus 로고
    • A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/ interferon-{alpha}2a vs placebo/interferon- {alpha}2a as firstline therapy in metastatic renal cell carcinoma
    • Escudier B, Koralewski P, Pluzanska A, et al. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/ interferon-{alpha}2a vs placebo/interferon- {alpha}2a as firstline therapy in metastatic renal cell carcinoma. J Clin Oncol (Meeting Abstracts) 2007; 25: 3.
    • (2007) J Clin Oncol (Meeting Abstracts) , vol.25 , pp. 3
    • Escudier, B.1    Koralewski, P.2    Pluzanska, A.3
  • 19
    • 35548997095 scopus 로고    scopus 로고
    • Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT)
    • Hutson TE, Davis ID, Machiels JP, et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT). J Clin Oncol (Meeting Abstracts) 2007; 25: 5031.
    • (2007) J Clin Oncol (Meeting Abstracts) , vol.25 , pp. 5031
    • Hutson, T.E.1    Davis, I.D.2    Machiels, J.P.3
  • 20
    • 55849119731 scopus 로고    scopus 로고
    • Sridhar SS, Hotte SJ, Mackenzie MJ, et al. Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): A trial of the PMH Phase II Consortium. J Clin Oncol (Meeting Abstracts) 2007; 25: 5093.
    • Sridhar SS, Hotte SJ, Mackenzie MJ, et al. Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): A trial of the PMH Phase II Consortium. J Clin Oncol (Meeting Abstracts) 2007; 25: 5093.
  • 21
    • 35549007093 scopus 로고    scopus 로고
    • Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib
    • Rini BI, Wilding GT, Hudes G, et al. Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib. J Clin Oncol (Meeting Abstracts) 2007; 25: 5032.
    • (2007) J Clin Oncol (Meeting Abstracts) , vol.25 , pp. 5032
    • Rini, B.I.1    Wilding, G.T.2    Hudes, G.3
  • 22
    • 47249134321 scopus 로고    scopus 로고
    • Perifosine (P), active as a single agent for renal cell carcinoma (RCC), now in phase I trials combined with tyrosine kinase inhibitors (TKI)
    • Stephenson J, Schreeder M, Waples J, et al. Perifosine (P), active as a single agent for renal cell carcinoma (RCC), now in phase I trials combined with tyrosine kinase inhibitors (TKI). J Clin Oncol (Meeting Abstracts) 2007; 25: 15622.
    • (2007) J Clin Oncol (Meeting Abstracts) , vol.25 , pp. 15622
    • Stephenson, J.1    Schreeder, M.2    Waples, J.3
  • 23
    • 33749257071 scopus 로고    scopus 로고
    • A phase I/II trial of sorafenib (S) with bevacizumab (B) in metastatic renal cell cancer (mRCC patients (Pts)
    • Sosman JA, Flaherty K, Atkins MB, et al. A phase I/II trial of sorafenib (S) with bevacizumab (B) in metastatic renal cell cancer (mRCC patients (Pts). J Clin Oncol (Meeting Abstracts) 2006; 24: 3031.
    • (2006) J Clin Oncol (Meeting Abstracts) , vol.24 , pp. 3031
    • Sosman, J.A.1    Flaherty, K.2    Atkins, M.B.3
  • 24
    • 34548229506 scopus 로고    scopus 로고
    • Sorafenib With Interferon Alfa-2b As First-Line Treatment of Advanced Renal Carcinoma: A Phase II Study of the Southwest Oncology Group
    • Ryan CW, Goldman BH, Lara PN, Jr., et al. Sorafenib With Interferon Alfa-2b As First-Line Treatment of Advanced Renal Carcinoma: A Phase II Study of the Southwest Oncology Group. J Clin Oncol 2007; 25: 3296-301.
    • (2007) J Clin Oncol , vol.25 , pp. 3296-3301
    • Ryan, C.W.1    Goldman, B.H.2    Lara Jr., P.N.3
  • 26
    • 35548945707 scopus 로고    scopus 로고
    • Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)
    • Feldman DR, Kondagunta GV, Ronnen EA, et al. Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol (Meeting Abstracts) 2007; 25: 5099.
    • (2007) J Clin Oncol (Meeting Abstracts) , vol.25 , pp. 5099
    • Feldman, D.R.1    Kondagunta, G.V.2    Ronnen, E.A.3
  • 27
    • 36749098248 scopus 로고    scopus 로고
    • Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results
    • Merchan JR, Liu G, Fitch T, et al. Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results. J Clin Oncol (Meeting Abstracts) 2007; 25: 5034.
    • (2007) J Clin Oncol (Meeting Abstracts) , vol.25 , pp. 5034
    • Merchan, J.R.1    Liu, G.2    Fitch, T.3
  • 28
    • 41149152686 scopus 로고    scopus 로고
    • Phase I study of PTK787/ ZK222584 (PTK/ZK) and RAD001 for patients with advanced solid tumors and dose expansion in renal cell carcinoma patients
    • Speca JC, Mears AL, Creel PA, et al. Phase I study of PTK787/ ZK222584 (PTK/ZK) and RAD001 for patients with advanced solid tumors and dose expansion in renal cell carcinoma patients. J Clin Oncol (Meeting Abstracts) 2007; 25: 5039.
    • (2007) J Clin Oncol (Meeting Abstracts) , vol.25 , pp. 5039
    • Speca, J.C.1    Mears, A.L.2    Creel, P.A.3
  • 29
    • 33845571367 scopus 로고    scopus 로고
    • Antitumor effects of sorafenib and sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC) who had prior therapy with anti-angiogenic agents
    • Tamaskar I, Shaheen P, Wood L, et al. Antitumor effects of sorafenib and sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC) who had prior therapy with anti-angiogenic agents. J Clin Oncol (Meeting Abstracts) 2006; 24: 4597.
    • (2006) J Clin Oncol (Meeting Abstracts) , vol.24 , pp. 4597
    • Tamaskar, I.1    Shaheen, P.2    Wood, L.3
  • 30
    • 35549008792 scopus 로고    scopus 로고
    • Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients
    • Sablin MP, Bouaita L, Balleyguier C, et al. Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients. J Clin Oncol (Meeting Abstracts) 2007; 25: 5038.
    • (2007) J Clin Oncol (Meeting Abstracts) , vol.25 , pp. 5038
    • Sablin, M.P.1    Bouaita, L.2    Balleyguier, C.3
  • 31
    • 36549059204 scopus 로고    scopus 로고
    • Sequential therapy with sorafenib and sunitinib in renal cell carcinoma
    • Dham A, Dudek AZ. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. J Clin Oncol (Meeting Abstracts) 2007; 25: 5106.
    • (2007) J Clin Oncol (Meeting Abstracts) , vol.25 , pp. 5106
    • Dham, A.1    Dudek, A.Z.2
  • 32
    • 0034039255 scopus 로고    scopus 로고
    • Interferon in metastatic renal cell carcinoma
    • Fossa SD. Interferon in metastatic renal cell carcinoma. Semin Oncol 2000; 27: 187-93.
    • (2000) Semin Oncol , vol.27 , pp. 187-193
    • Fossa, S.D.1
  • 33
    • 7144227930 scopus 로고    scopus 로고
    • Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie
    • Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998; 338: 1272-8.
    • (1998) N Engl J Med , vol.338 , pp. 1272-1278
    • Negrier, S.1    Escudier, B.2    Lasset, C.3
  • 34
    • 3242814615 scopus 로고    scopus 로고
    • Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma
    • Fossa SD, Mickisch GH, De Mulder PH, et al. Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma. Cancer 2004; 101: 533-40.
    • (2004) Cancer , vol.101 , pp. 533-540
    • Fossa, S.D.1    Mickisch, G.H.2    De Mulder, P.H.3
  • 36
    • 34547411610 scopus 로고    scopus 로고
    • Cost-effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma
    • Gao X, Reddy P, Dhanda R, et al. Cost-effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma. J Clin Oncol (Meeting Abstracts) 2006; 24: 4604.
    • (2006) J Clin Oncol (Meeting Abstracts) , vol.24 , pp. 4604
    • Gao, X.1    Reddy, P.2    Dhanda, R.3
  • 37
    • 2142695181 scopus 로고    scopus 로고
    • Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: A Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)
    • Atzpodien J, Kirchner H, Jonas U, et al. Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 2004; 22: 1188-94.
    • (2004) J Clin Oncol , vol.22 , pp. 1188-1194
    • Atzpodien, J.1    Kirchner, H.2    Jonas, U.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.